See more : NerdWallet, Inc. (NRDS) Income Statement Analysis – Financial Results
Complete financial analysis of Vicore Pharma Holding AB (publ) (VICO.ST) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Vicore Pharma Holding AB (publ), a leading company in the Biotechnology industry within the Healthcare sector.
- Klotho Neurosciences, Inc. (KLTOW) Income Statement Analysis – Financial Results
- Lion Travel Service Co., Ltd. (2731.TW) Income Statement Analysis – Financial Results
- Gencell Ltd (GNCL.TA) Income Statement Analysis – Financial Results
- Traws Pharma, Inc. (TRAW) Income Statement Analysis – Financial Results
- Cochin Shipyard Limited (COCHINSHIP.NS) Income Statement Analysis – Financial Results
Vicore Pharma Holding AB (publ) (VICO.ST)
About Vicore Pharma Holding AB (publ)
Vicore Pharma Holding AB (publ) engages in the research and development of pharmaceutical products for the treatments for rare lung diseases. The company is developing VP01, a small molecule compound for oral administration that is in phase II clinical trial for the treatment of interstitial lung diseases, idiopathic pulmonary fibrosis (IPF), systemic sclerosis, and COVID-19; and VP02, a formulation and delivery route for an existing immunomodulatory compound, which is preclinical trials to treat patients with IPF. It has a cooperation and development agreement with Emeriti Bio AB; license agreement with Nanologica AB (publ); and a collaboration agreement with Alex Therapeutics AB for the development and clinical validation of a digital therapeutic (DTx) built on the Alex DTx platform. The company was formerly known as Mintage Scientific AB. Vicore Pharma Holding AB (publ) was founded in 2000 and is headquartered in Gothenburg, Sweden.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 508.00K | 932.00K | 852.00K | 840.00K | 1.57M | 3.31M | 3.31K |
| Cost of Revenue | 3.42M | 3.61M | 3.60M | 3.54M | 1.34M | 21.76M | -2.65M | -1.22M | -816.00K | -720.00K | -720.00K | 2.98K |
| Gross Profit | -3.42M | -3.61M | -3.60M | -3.54M | -1.34M | -21.25M | 3.58M | 2.07M | 1.66M | 2.29M | 4.03M | 339.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -4,182.68% | 383.80% | 243.31% | 197.14% | 145.83% | 121.79% | 10.23% |
| Research & Development | 272.87M | 249.97M | 271.81M | 142.02M | 67.05M | 20.46M | 17.56M | 12.26M | 3.87M | 0.00 | 0.00 | 0.00 |
| General & Administrative | 36.92M | 28.38M | 20.20M | 24.99M | 26.88M | 8.62M | 5.43M | 5.01M | 3.36M | 4.04M | 2.85M | 0.00 |
| Selling & Marketing | 7.67M | 9.15M | 1.40M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 44.60M | 37.53M | 21.61M | 24.99M | 26.88M | 8.62M | 5.43M | 5.01M | 3.36M | 4.04M | 2.85M | 2.58K |
| Other Expenses | 617.00K | 0.00 | 0.00 | -17.54M | 91.00K | 13.01M | 10.53M | 3.72M | 2.84M | 1.66M | -160.00K | 0.00 |
| Operating Expenses | 321.51M | 287.49M | 293.42M | 149.47M | 94.01M | 42.09M | 15.96M | 8.72M | 6.20M | 5.70M | 2.69M | 3.30K |
| Cost & Expenses | 321.51M | 287.49M | 293.42M | 149.47M | 94.01M | 42.09M | 13.32M | 7.50M | 5.38M | 4.98M | 1.97M | 6.27K |
| Interest Income | 10.54M | 913.00K | 646.00K | 815.00K | 163.00K | 0.00 | 0.00 | 0.00 | 0.00 | 51.00K | 11.00K | 202.00 |
| Interest Expense | 358.00K | 8.00K | 11.00K | 6.00K | 27.00K | 352.00K | 62.00K | 3.00K | 27.00K | 105.00K | 219.00K | 0.00 |
| Depreciation & Amortization | 3.42M | 3.61M | 3.60M | 3.54M | 1.34M | 7.00K | 7.00K | 6.00K | 6.00K | 36.00K | 40.00K | 38.00 |
| EBITDA | -317.47M | -286.20M | -293.13M | -143.77M | -92.51M | -38.25M | -23.81M | -6.65M | -4.54M | -4.93M | -1.46M | -1.74K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -4,922.44% | -1,371.89% | -779.69% | -540.12% | 880.20% | -40.67% | -52.60% |
| Operating Income | -321.51M | -290.73M | -294.82M | -149.54M | -94.01M | -44.28M | -12.79M | -6.65M | -4.54M | -5.34M | -3.00M | -1.78K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -8,716.54% | -1,372.64% | -780.40% | -540.83% | -339.91% | -90.62% | -53.74% |
| Total Other Income/Expenses | 10.18M | 1.92M | -1.92M | 2.22M | 685.00K | 22.60M | 4.35M | -3.00K | -27.00K | 19.03M | 1.39M | -1.38K |
| Income Before Tax | -311.33M | -288.81M | -296.74M | -147.32M | -93.33M | -21.68M | -12.86M | -6.65M | -4.57M | 13.69M | -1.60M | -3.16K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -4,267.91% | -1,379.29% | -780.75% | -544.05% | 871.23% | -48.50% | -95.29% |
| Income Tax Expense | -384.00K | -384.00K | -254.00K | -453.00K | -245.00K | 20.26M | -410.00K | 0.00 | 0.00 | 18.77M | 590.00K | 0.00 |
| Net Income | -310.94M | -288.42M | -296.48M | -146.86M | -93.08M | -21.68M | -12.86M | -6.65M | -4.57M | 13.69M | -1.60M | -3.16K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -4,267.91% | -1,379.29% | -780.75% | -544.05% | 871.23% | -48.50% | -95.29% |
| EPS | -3.22 | -3.99 | -4.25 | -2.71 | -2.16 | -0.95 | -0.76 | -0.47 | -0.32 | 1.06 | -0.12 | -0.09 |
| EPS Diluted | -3.22 | -3.99 | -4.25 | -2.71 | -2.16 | -0.95 | -0.76 | -0.47 | -0.32 | 1.06 | -0.12 | -0.09 |
| Weighted Avg Shares Out | 96.56M | 72.21M | 69.68M | 54.25M | 43.04M | 22.88M | 16.99M | 14.03M | 14.08M | 12.95M | 12.95M | 34.28K |
| Weighted Avg Shares Out (Dil) | 96.56M | 72.21M | 69.68M | 54.25M | 43.04M | 22.88M | 16.99M | 14.03M | 14.08M | 12.95M | 12.95M | 34.28K |
Source: https://incomestatements.info
Category: Stock Reports